STOCK TITAN

Large holders report 6.5% and 6.9% stakes in Caris Life Sciences (CAI)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Caris Life Sciences, Inc. received an updated ownership report from investment entities affiliated with TSSP Sub-Fund HoldCo, LLC and Alan Waxman. As of December 31, 2025, TSSP Sub-Fund HoldCo reports beneficial ownership of 18,416,128 shares of common stock, representing 6.5% of the company. Alan Waxman reports beneficial ownership of 19,385,399 shares, or 6.9% of the outstanding common stock.

The ownership percentages are calculated using 282,146,923 shares outstanding as of November 3, 2025, as disclosed in the company’s Form 10-Q. The filing explains that the reported holdings are spread across several affiliated investment vehicles and that each reporting person formally disclaims beneficial ownership of the securities held by those entities.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



TSSP Sub-Fund HoldCo, LLC
Signature:/s/ Joshua Peck
Name/Title:Joshua Peck, Vice President
Date:02/13/2026
Alan Waxman
Signature:/s/ Joshua Peck
Name/Title:Joshua Peck, on behalf of Alan Waxman (*)
Date:02/13/2026

Comments accompanying signature: Joshua Peck is signing on behalf of Mr. Waxman pursuant to an authorization and designation letter dated December 31, 2024.
Exhibit Information

Exhibit 1 - Agreement of Joint Filing (previously filed) Exhibit 2 - Authorization and Designation Letter, dated December 31, 2024, by Alan Waxman (previously filed)

FAQ

What ownership stake in Caris Life Sciences (CAI) does TSSP Sub-Fund HoldCo report?

TSSP Sub-Fund HoldCo reports beneficial ownership of 18,416,128 Caris Life Sciences common shares, equal to 6.5% of the company. This percentage is based on 282,146,923 shares outstanding as of November 3, 2025, from the company’s Form 10-Q.

How many Caris Life Sciences (CAI) shares does Alan Waxman report owning?

Alan Waxman reports beneficial ownership of 19,385,399 shares of Caris Life Sciences common stock, representing 6.9% of the class. This stake is calculated using 282,146,923 shares outstanding as of November 3, 2025, per the company’s Form 10-Q.

How are the reported Caris Life Sciences (CAI) shares held across entities?

The filing states that 4,521,074 shares are held by Barnett Equity Holdings, 969,271 by Sixth Street Specialty Lending Inc., 3,086,022 by TOP III Barnett Investments, 8,031,613 by Barnett Equity Holdings II, and 2,777,419 by TAO Barnett Investments, with various affiliated managers.

What share count did Caris Life Sciences (CAI) use to calculate ownership percentages?

Ownership percentages are based on 282,146,923 common shares outstanding as of November 3, 2025. This share count comes from Caris Life Sciences’ Quarterly Report on Form 10-Q filed with the SEC on November 5, 2025, and is cited directly in the ownership section.

Do the reporting persons claim full beneficial ownership of Caris Life Sciences (CAI) shares?

The filing explains that each reporting person disclaims beneficial ownership of securities held directly by the listed investment entities. It also notes that submitting this statement does not constitute an admission of beneficial ownership for Section 13(d) purposes or any other purpose.

What type of Caris Life Sciences (CAI) security is covered in this ownership report?

The report covers common stock of Caris Life Sciences, with a par value of $0.001 per share. The filing identifies the security class as common stock and references the CUSIP number 142152107, tying all reported ownership figures to this security class.
Caris Life Sciences, Inc.

NASDAQ:CAI

CAI Rankings

CAI Latest News

CAI Latest SEC Filings

CAI Stock Data

5.82B
115.64M
Biotechnology
Services-medical Laboratories
Link
United States
IRVING